Inhibiting CDS2 Selectively Kills CDS1-deficient Cancer Cells – The Netherlands Cancer Institute
The Netherlands Cancer Institute shared a post on LinkedIn:
“Researchers at the Netherlands Cancer Institute have identified a novel vulnerability present in about 50% of cancers. PhD candidate Tim Arnoldus, in the group of Daniel Peeper, took an innovative approach: instead of traditional lab screens, he used large public datasets and advanced computational analyses to pinpoint new cancer dependencies. This led to the discovery of a synthetic lethal interaction between the genes CDS1 and CDS2.
Many aggressive tumors lose CDS1 function and become fully reliant on CDS2 for survival.
Inhibiting CDS2 selectively kills these cancer cells while sparing healthy tissue, a concept similar to how PARP inhibitors work in BRCA-mutated cancers.
The findings, published in Nature Genetics, provide a strong foundation for developing new targeted therapies for difficult-to-treat tumors.
More posts featuring the Netherlands Cancer Institute on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023